Navigation Links
First Ever Patch Drug To Treat Parkinsons Symptoms Approved

The U.S. Food and Drug administration on Wednesday approved a new patch-drug, the first ever medicine to treat the symptoms of Parkinson's disease . Known by the name Neupro, the once-daily patch is manufactured by Schwarz Pharma AG. The patch contains a drug called rotigotine, which has not been sold before in the United States.

Parkinsons disease (PD) is a degenerative disorder of the central nervous system that often impairs the sufferer's motor skills and speech. It is characterized by muscle rigidity, tremor, a slowing of physical movement and, in extreme cases, a loss of physical movement.

In a healthy brain, certain brain cells produce a chemical called dopamine, which helps the brain coordinate the body's movements while in the patients who suffer from Parkinson's, dopamine-producing brain cells cannot survive. Dopamine is crucial for the communication between cells that control muscle movement hence the sufferers of PD are often seen trembling.

Accordingly, the rotigotine present in the Neupro patch works by activating dopamine receptors in the brain, imitating the neurotransmitter's effect. The FDA determined the effectiveness of Neupro's by three studies that included 1,154 patients with early Parkinson's disease who were not taking other Parkinson's medications.

Rotigotine is a member of a class of drugs called dopamine agonists, which mimic dopamine's effects.

Other Parkinson's disease drugs are given orally. Those drugs are effective, but some patients experience a wearing-off effect at the end of each dose. The Parkinson's patch is designed to solve that problem.

However, the patch also has some side effects that include skin reactions at the patch site, dizziness, nausea, vomiting, drowsiness and insomnia. Also, the patient using this patch can experience a sudden onset of sleep while doing some activities like driving or operating machinery. Other side effects also include hallucinat ions and decreased blood pressure when standing up.

An estimated 1 million people in the U.S. have Parkinson's, with an additional 60,000 cases diagnosed each year.


'"/>




Related medicine news :

1. First Vaccine Designed for Africa Cleared for Testing in Humans
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. First human clone is near
4. First Artificial Heart patient has Major setback
5. First head-to-head trials of once weekly Fosamax and Actonel therapies
6. WHO Declares Vietnam First Country to Control SARS
7. Russia Reports First SARS Case
8. Hope for First New Melanoma Treatment in Decades
9. First global SARS meet opens
10. Stanford Medical Center Implements The First Virtual Cardiac Ultrasound
11. Hyderabad To Have Asia’s First Catheter Making Uni
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... ... ... sleep affects much more than energy – it also has mental and physical benefits. According ... reaction time, which can increase the risk of having a car accident. , This ... NSF to help you sleep better and feel better:, , Turn ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology: